Beck Greener
Firm overview:
Beck Greener has long occupied a distinctive position in the UK patent market, pairing boutique scale with strong technical capability. The practice is particularly renowned for European Patent Office (EPO) oppositions and appeals, where it regularly competes against—and often outperforms—much larger firms. Beck Greener enhanced its EPO capabilities, particularly in the life sciences fields, with its 2025 acquisition of well-established UK patent practice Graham & Watt. The firm operates as an extension of clients’ in-house teams, combining commercial acumen with technical expertise.
Team overview:
Beck Greener’s profile is strongest in technically demanding EPO work, where it is known for a strong success rate in oppositions and appeals.
Catherine Jewell, who focuses her patent practice on the chemicals field, “delivers the best results” according to one client. Her experience spans a broad range of technologies, including instrumentation, energy storage, organic chemistry, materials chemistry, ceramics and polymers, and pharmaceutical chemistry.
The appointment of former Chartered Institute of Patent Attorneys (CIPA) president Matt Dixon in 2024 as executive chair significantly strengthened the firm’s contentious and strategic capabilities, particularly in Unified Patent Court (UPC) proceedings.
Key matters:
- Rocep-Lusol: Unified Patent Court revocation action
Beck Greener defended Rocep-Lusol before the UPC, defeating a standalone revocation action against its European patent covering eco-friendly adhesive dispensing technology. The patent was upheld, and the related appeal and non-infringement proceedings were later withdrawn following settlement.
- Tillotts Pharma: Indian Patent Office divisional patent appeal
The team overturned an Indian Patent Office decision refusing Tillotts Pharma’s divisional patent application, securing grant of the patent and reinforcing the client’s exclusivity over key pharmaceutical drug delivery technologies.
- Tillotts Pharma: Global pharmaceutical patent portfolio and EPO opposition
Beck Greener manages Tillotts Pharma’s global pharmaceutical patent portfolio across more than 80 jurisdictions and advised on a strategically important EPO opposition, supporting the protection and lifecycle management of the client’s international drug delivery technology portfolio.
Clients:
Bruker Daltonik, FabRx, Intract Pharma, Rocep-Lusol, Tillotts Pharma, UB Infrastructure, White Motorcycle Concepts
